Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Br J Dermatol 2024;190:477–85 Doi: 10.1093/bjd/ljad429.
Three years of safety data were pooled from three Phase III trials (BE VIVID, BE READY and BE SURE) and their ongoing OLE (BE BRIGHT), then allocated according to PASI response, treatment, and dose. Bimekizumab was administered as a 320 mg dose Q4W or Q8W.
Keywords:
